Obsidian (OBX) Director Robert W. Ross Receives 37,653-Share Award

What Happened

• Robert W. Ross, a director of Obsidian Therapeutics, received a grant/award of derivative rights covering 37,653 shares on 2026-08-03. The reported acquisition price is $0.00, indicating an equity award (the Form 4 notes these are options). This was an award grant — not a purchase or sale — so no cash changed hands and no shares were sold.

Key Details

• Transaction date: 2026-08-03; Filing date: 2026-08-05 (Form 4) — appears timely.
• Reported amount: 37,653 underlying shares; reported price: $0.00 (derivative award).
• Shares owned after transaction: not specified in the information provided in this summary.
• Footnote: The shares underlying this option vest and become exercisable on the earlier of (i) the one-year anniversary of the grant date or (ii) the issuer's next annual meeting, subject to continued service by the director.
• No indication of a 10b5-1 plan, tax withholding, or immediate sale in the provided filing.

Context

• This is a derivative award (option-like grant) that vests in the future; it does not represent an immediate sale or purchase. Such grants to directors are commonly part of routine compensation and do not by themselves signal a buy or sell decision. No exercise or cashless sale occurred in this filing.